Loading...
•
Dec 31, 2021
Capricor Q4 2021 Earnings Report
Capricor reported financial results for the fourth quarter and full year 2021 and provided a corporate update.
Key Takeaways
Capricor Therapeutics reported a net loss of $6.2 million, or $0.26 per share, for the fourth quarter of 2021. As of December 31, 2021, the company's cash and cash equivalents totaled $34.9 million.
Entered exclusive partnership with Nippon Shinyaku for commercialization and distribution of CAP-1002 for Duchenne Muscular Dystrophy in United States.
Capricor to receive upfront payment of $30 million with additional milestone payments of up to $705 million.
Pivotal Phase 3, HOPE-3 Trial Initiation Underway.
Phase 2 INSPIRE Top-Line Data Expected by End of First Quarter of 2022.
Forward Guidance
Capricor believes that based on the current operating plan and financial resources, the Company expects that the cash and cash equivalents will be sufficient to cover expenses and capital requirements for at least two years.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...